Patents Represented by Attorney, Agent or Law Firm Mark R. Daniel
  • Angiogenesis inhibitors
    Patent number: 6228871
    Abstract: The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: May 8, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Randall W. Hungate, William F. Hoffman, William R. Huckle, Richard L. Kendall, Kenneth A. Thomas, Jr.
  • 11-hydroxysordarin and a process for producing it using actinomyces SSP
    Patent number: 6228622
    Abstract: 11-hydroxysordarin, biotransformation product of a fermentation with sordarin and Actinomyces spp., (Merck Culture Collection MA7235) ATCC No. 202103 is an antifungal agent. This compound may be useful in the treatment of diseases caused by fungal pathogens such as Candida albicans.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: May 8, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Michael G. Sturr, Michel M. Chartrain, Guy H. Harris, Jennifer Nielsen-Kahn, Brian Heimbuch
  • Antagonists of gonadotropin releasing hormone
    Patent number: 6228867
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: May 8, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Thomas F. Walsh, Mark T. Goulet, Feroze Ujjainwalla
  • Rubber stopper separator
    Patent number: 6220450
    Abstract: A device to separate rubber stoppers that have adhered together, typically as a result of sterilization. The device contains a hopper, a pair of rollers and a mechanism to turn the rollers. The rollers are hexagonal-shaped and each face has a scalloped concavity. The adhering stoppers are gravity-fed into the rollers from the hopper, where they are compressed and a shearing force is applied to separate the adherent stoppers. The separated stoppers are then collected for further processing.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: April 24, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Kristian N. Weeder, Gordon D. Deacon
  • Carbapenem antibacterial compositions and methods of the treatment
    Patent number: 6221859
    Abstract: The present invention relates to novel 2-(naphthosultamyl)methyl-carbapenem antibacterial agents or pharmaceutically acceptable salts thereof in combination with other &bgr;-lactams, which are useful in treating and preventing enterococcal infections. The combinations have anti-PBP5 activity as well as activity against the critical PBPs of sensitive isolates. The antibacterial compositions of the present invention thus comprise an important contribution to therapy for treating infections caused by these difficult to control pathogens. This combination is also useful against gram positive microorganisms, especially methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE), and methicillin resistant coagulase negative Staphylococci (MRCNS).
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: April 24, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Karen L. Dorso, Jesse J. Jackson, Charles J. Gill, Joyce Kohler, Lynn L. Silver
  • Methods of treating or preventing cardiac arrhythmia
    Patent number: 6214810
    Abstract: This application discloses a method of treating or preventing atrial arrhythmias which utilizes compounds which are blockers of the ultra-rapidly-activating delayed rectifier K+ current (IKur) of the human atrium in a use-dependent and/or rate dependent manner, and which provide the selective block preferentially at fast heart rates so that the effect is realized or maximized when required.
    Type: Grant
    Filed: April 19, 1999
    Date of Patent: April 10, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Bernard Fermini, Joseph J. Lynch, Jr., Joseph J. Salata, Richard J. Swanson
  • Benzodiazepine derivatives as antiarrhythmic agents
    Patent number: 6214823
    Abstract: This invention is concerned with novel compounds represented by structural formula I which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: April 10, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, John W. Butcher, David A. Claremon, Harold G. Selnick
  • Methods of treating or preventing cardiac arrhythmia
    Patent number: 6214809
    Abstract: A method of treating or preventing supraventricular tachyarrhythmias is disclosed which comprises the use of a compound which selectively blocks the ultra-rapidly-activating delayed rectifier K+ current (IKur) of the human atrium.
    Type: Grant
    Filed: April 19, 1999
    Date of Patent: April 10, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Bernard Fermini, Joseph J. Lynch, Jr., Joseph J. Salata, Richard J. Swanson
  • Antagonists of gonadotropin releasing hormone
    Patent number: 6211224
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: October 26, 1998
    Date of Patent: April 3, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Lin Chu, Mark Goulet, Thomas F. Walsh, Matthew J. Wyvratt, Stephanie L. Witkin
  • Substituted imidazoles having cytokine inhibitory activity
    Patent number: 6207687
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which may be useful for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: March 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, David A. Claremon
  • Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
    Patent number: 6207823
    Abstract: The present invention relates to tricyclic carbapenem antibacterial agents in which the carbapenem nucleus is fused to a 6 membered carbocyclic ring. The compound is further substituted with various substituent groups including at least one cationic group. The compounds are represented by formula I: Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: March 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Frank P. Dininno, Milton L. Hammond
  • Modified PE40 toxin fusion proteins
    Patent number: 6207798
    Abstract: We have modified PE40 toxin by removing at least two of its four cysteine amino acid residues and have formed hybrid molecules containing modified PE40 linked to a cell recognition protein that can be an antibody, a growth factor, a hormone, a lymphokine, or another polypeptide cell recognition protein for which a specific cellular receptor exists whereby the modified PE40 toxin is directed to cell types having receptors for the cell recognition protein linked to the modified PE40.
    Type: Grant
    Filed: February 10, 1997
    Date of Patent: March 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Allen I. Oliff, Gwynneth M. Edwards, Deborah D. Jones
  • Process for making intermediate aldehydes
    Patent number: 6201158
    Abstract: The present invention relates to a process for making propargylic alcohols by zinc-mediated catalytic, asymmetric addition of acetylenes to aldehydes.
    Type: Grant
    Filed: May 27, 1999
    Date of Patent: March 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Zhen Li, Ann Decamp, Veena Upadhyay
  • Antagonists of gonadotropin releasing hormone
    Patent number: 6200957
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: July 14, 1998
    Date of Patent: March 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Wallace T. Ashton, Lin Chu, Michael H. Fisher, Peter Lin, Mitree M. Ponpipom, Matthew J. Wyvratt, Narindar N. Girotra, Jonathan Young
  • Method for reducing mortality with an angiotensin II antagonist
    Patent number: 6201002
    Abstract: Angiotensin II receptor antagonists are useful in reducing and preventing mortality and sudden cardiac death in symptomatic heart failure patients. Losartan potassium has been shown to reduce mortality and sudden cardiac death in this patient population. Additionally, losartan potassium has been shown to reduce the need for hospitalization of symptomatic heart failure patients.
    Type: Grant
    Filed: January 6, 1998
    Date of Patent: March 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Polly A. Beere, Paul I. Chang, Bertram Pitt, Eva J. Rucinska, Robert Segal, Divakar Sharma, Duane B. Snavely
  • Antagonists of gonadotropin releasing hormone
    Patent number: 6197975
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: March 6, 2001
    Assignee: Merck & Co. , Inc.
    Inventors: Mark Goulet, Wallace T. Ashton, Lin Chu, Michael H. Fisher, Matthew J. Wyvratt
  • Benzamide potassium channel inhibitors
    Patent number: 6194458
    Abstract: This invention relates to benzamide potassium channel inhibitors of general structural Formula I. The compounds of this invention are useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and related afflictions, diseases and illnesses, and cardiac arrhythmias. Also within the scope of this invention are pharmaceutical formulations comprising a compound of Formula I and a pharmaceutical carrier, as well as pharmaceutical formulations comprising a compound of Formula I, one or more immunosuppressive compounds and a pharmaceutical carrier.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: February 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Baker, Jianming Bao, Frank Kayser, Andrew Kotliar, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Process for synthesizing carbapenem intermediates
    Patent number: 6194568
    Abstract: The invention describes an improved process for synthesizing 1-&bgr;-methyl-2-hydroxymethyl substituted carbapenems as key intermediates for the synthesis of anti-MRSA carbapenem antibiotics. The synthesis eliminates the use of BU3SnCH2OH and HMPA, which are toxic substances and not amenable to industrial scale production. The novel intermediates are also within the scope of this invention. The invention relates to the synthesis of a compound of formula 3: wherein R1 represents H or a suitable protecting group for an alcohol; R2 represents H or methyl; and R5 represents a carboxy protecting group as well as the compounds made therein.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: February 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark S. Jensen, Yi Xiao, Chunhua Yang, Kenneth M. Wells, Nobuyoshi Yasuda
  • 6-azaindole compounds as antagonists of Gonadotropin releasing hormone
    Patent number: 6180642
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: January 30, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Thomas F. Walsh, Feroze Ujjainwalla
  • Stabilized carbapenem intermediates and improved process for carbapenem synthesis
    Patent number: 6180783
    Abstract: A stabilized carbapenem intermediate compound represented by the formula 1: or a salt thereof is disclosed, wherein P represents a carboxyl protecting group and X represents a charge balancing group. In addition, a process for synthesizing a compound represented by formula 2: is disclosed wherein X+ is a charge balancing group, comprising: deprotecting a compound of the formula 1 to produce a compound 2.
    Type: Grant
    Filed: June 9, 1998
    Date of Patent: January 30, 2001
    Assignee: Merck & Co., Inc.
    Inventors: John M. Williams, Renato T. Skerlj, Karel M. J. Brands, Ulf H. Dolling, Ronald B. Jobson